Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01313923

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus

Sponsor: University of California, Irvine

Conditions Pemphigus

Interventions Sirolimus (formerly known as Rapamycin)

Updated 7 times since 2017 Last updated: May 8, 2017 Started: Feb 28, 2011 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of funding

Other terminated trials from University of California, Irvine

See all terminations from University of California, Irvine

A EARLY_PHASE1 clinical study on Pemphigus, this trial is terminated or withdrawn. The trial is conducted by University of California, Irvine and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated EARLY_PHASE1
Dec 2021 — Jul 2024 [monthly]

Terminated EARLY_PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated Phase 0

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of California, Irvine

Data source: University of California, Irvine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Irvine, United States